• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

AMLODIPINE Drug Record

  • Summary
  • Interactions
  • Claims
  • AMLODIPINE chembl:CHEMBL1491 Approved

    Alternate Names:

    AMLODIPINE
    NORVASC
    CKD-330 COMPONENT AMLODIPINE
    NORVAS
    HGP0904
    ISTIN
    ASTUDAL 5
    HGP-0904

    Drug Info:

    Year of Approval 1992
    Drug Class antihypertensive agents
    Drug Class Small molecule
    Drug Indications antihypertensive agent, cardiovascular agent
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antihypertensive agent
    (1 More Sources)

    Publications:

    Irvin MR et al., 2010, Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study., J Hypertens
    Peterson et al., 2006, Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore., Mol. Pharmacol.
    Kim KA et al., 2006, Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects., Clin Pharmacol Ther
    Sinnegger-Brauns et al., 2009, Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms., Mol. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Tang L et al., 2016, Structural basis for inhibition of a voltage-gated Ca<sup>2+</sup> channel by Ca<sup>2+</sup> antagonist drugs., Nature
    Bodi I et al., 2005, The L-type calcium channel in the heart: the beat goes on., J Clin Invest
    Furukawa et al., 1997, Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine., Br. J. Pharmacol.
    Qu et al., 1998, Comparison of binding affinities of omega-conotoxin and amlodipine to N-type Ca2+ channels in rat brain., Zhongguo Yao Li Xue Bao
    Furukawa et al., 1999, Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes., J. Pharmacol. Exp. Ther.
    Miyashita et al., 2010, A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine., Eur. J. Pharmacol.
    Ogihara et al., 2009, Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling., Arzneimittelforschung
    Murakami et al., 2001, Antinociceptive action of amlodipine blocking N-type Ca2+ channels at the primary afferent neurons in mice., Eur. J. Pharmacol.
    Godfraind T, 2017, Discovery and Development of Calcium Channel Blockers., Front Pharmacol
    Lynch AI et al., 2008, Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension., JAMA
  • AMLODIPINE   NPPA

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18212314


    Sources:
    PharmGKB

  • AMLODIPINE   CACNA1B

    Interaction Score: 1.47

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    9249249 10374627 10525060 20097194 19634509 11426839 28611661


    Sources:
    TEND

  • AMLODIPINE   CACNB2

    Interaction Score: 1.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Tribenzor
    Novel drug target Established target
    Trial Name aliskiren + amlodipine,Tekamlo

    PMIDs:
    11752352


    Sources:
    TdgClinicalTrial

  • AMLODIPINE   CACNA2D1

    Interaction Score: 0.86

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name aliskiren + amlodipine,Tekamlo
    Novel drug target Established target
    Trial Name amlodipine besylate,Norvasc

    PMIDs:
    11752352


    Sources:
    TdgClinicalTrial TTD

  • AMLODIPINE   CACNA1C

    Interaction Score: 0.66

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name aliskiren + amlodipine,Tekamlo
    Novel drug target Established target
    Trial Name amlodipine besylate,Norvasc

    PMIDs:
    11752352 27556947 16322774


    Sources:
    TdgClinicalTrial

  • AMLODIPINE   CACNA1D

    Interaction Score: 0.43

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name aliskiren + amlodipine,Tekamlo
    Novel drug target Established target
    Trial Name amlodipine besylate,Norvasc

    PMIDs:
    19029287


    Sources:
    TdgClinicalTrial

  • AMLODIPINE   CACNG1

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • AMLODIPINE   AGT

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • AMLODIPINE   CACNA1S

    Interaction Score: 0.33

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name amlodipine besylate,Norvasc
    Novel drug target Established target
    Trial Name Amturnide

    PMIDs:
    16675661


    Sources:
    TdgClinicalTrial

  • AMLODIPINE   ACE

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20577119


    Sources:
    PharmGKB

  • AMLODIPINE   CYP3A5

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17178265


    Sources:
    PharmGKB

  • AMLODIPINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TdgClinicalTrial: AMLODIPINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antihypertensive agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • TEND: AMLODIPINE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Drug Class antihypertensive agents
    Year of Approval 1992

    Publications:

  • PharmGKB: amlodipine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Irvin MR et al., 2010, Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study., J Hypertens
    Kim KA et al., 2006, Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects., Clin Pharmacol Ther
    Lynch AI et al., 2008, Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension., JAMA

  • TTD: Amlodipine

    • Version: 2020.06.01

    Alternate Names:
    D08JIV TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1491

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21